Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Ray-Coquard

Showing results (251-260 of 550) with videos related to

Pageof 55
Sort By:
Plos One|April 6, 2018
The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma GroupLionel Perrier, Pauline Rascle, Magali Morelle, et al.
Bulletin Du Cancer|February 22, 2014
[To answer rare cancer issues. Geographical analysis of EMS sarcoma cohort in the Rhône-Alpes region]Yohan Fayet, Virginie Chasles, Françoise Ducimetière, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2006
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupMichael Leahy, Isabelle Ray-Coquard, Jaap Verweij, et al.
Bulletin Du Cancer|September 20, 2011
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective studyIrène Asmane, Jean-Emmanuel Kurtz, Agathe Bajard, et al.
The Lancet. Oncology|September 25, 2010
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trialAxel Le Cesne, Isabelle Ray-Coquard, Binh Nguyen Bui, et al.
Bulletin Du Cancer|March 2, 2023
[Uterine leiomyosarcoma - French guidelines from the GSF/NETSARC and TMRG groups]Bérénice Collineau, Catherine Genestie, Sabrina Croce, et al.
Metabolomics : Official Journal of the Metabolomic Society|November 9, 2024
Connecting the changing trace elements spectrum and survival in sarcoma: a pilot studyLaetitia Collet, Philippe Telouk, Francis Albarede, et al.
International Journal of Cancer|June 18, 2026
Limb Compression Therapy and Chemotherapy-Induced Peripheral Neuropathy in Women With Gynecologic Cancers: A Prospective Self-Controlled Study(NEURO-GLOVE Trial)Kadriye Başkurt, Galip Can Uyar, Enes Yeşilbaş, et al.
JCO Precision Oncology|June 26, 2023
Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian CarcinomaYann Christinat, Liza Ho, Sophie Clément, et al.
Targeted Oncology|May 26, 2015
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based ChemotherapyEvelyn Despierre, Ignace Vergote, Ryan Anderson, et al.
Pageof 55

Showing results (251-260 of 550) with videos related to

Sort By:
Pageof 55
Plos One|April 6, 2018
The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma GroupLionel Perrier, Pauline Rascle, Magali Morelle, et al.
Bulletin Du Cancer|February 22, 2014
[To answer rare cancer issues. Geographical analysis of EMS sarcoma cohort in the Rhône-Alpes region]Yohan Fayet, Virginie Chasles, Françoise Ducimetière, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2006
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupMichael Leahy, Isabelle Ray-Coquard, Jaap Verweij, et al.
Bulletin Du Cancer|September 20, 2011
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective studyIrène Asmane, Jean-Emmanuel Kurtz, Agathe Bajard, et al.
The Lancet. Oncology|September 25, 2010
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trialAxel Le Cesne, Isabelle Ray-Coquard, Binh Nguyen Bui, et al.
Bulletin Du Cancer|March 2, 2023
[Uterine leiomyosarcoma - French guidelines from the GSF/NETSARC and TMRG groups]Bérénice Collineau, Catherine Genestie, Sabrina Croce, et al.
Metabolomics : Official Journal of the Metabolomic Society|November 9, 2024
Connecting the changing trace elements spectrum and survival in sarcoma: a pilot studyLaetitia Collet, Philippe Telouk, Francis Albarede, et al.
International Journal of Cancer|June 18, 2026
Limb Compression Therapy and Chemotherapy-Induced Peripheral Neuropathy in Women With Gynecologic Cancers: A Prospective Self-Controlled Study(NEURO-GLOVE Trial)Kadriye Başkurt, Galip Can Uyar, Enes Yeşilbaş, et al.
JCO Precision Oncology|June 26, 2023
Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian CarcinomaYann Christinat, Liza Ho, Sophie Clément, et al.
Targeted Oncology|May 26, 2015
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based ChemotherapyEvelyn Despierre, Ignace Vergote, Ryan Anderson, et al.
Pageof 55